American Association for Cancer Research
Browse
cir-23-0486_supplementary_fig.s11_supps11.pdf (137.72 kB)

Supplementary Fig. S11 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Download (137.72 kB)
journal contribution
posted on 2024-04-02, 07:40 authored by Jiang Chen, Zohreh Amoozgar, Xin Liu, Shuichi Aoki, Zelong Liu, Sarah M. Shin, Aya Matsui, Alexei Hernandez, Zhangya Pu, Stefan Halvorsen, Pin-Ji Lei, Meenal Datta, Lingling Zhu, Zhiping Ruan, Lei Shi, Daniel Staiculescu, Koetsu Inoue, Lance L. Munn, Dai Fukumura, Peigen Huang, Slim Sassi, Nabeel Bardeesy, Won Jin Ho, Rakesh K. Jain, Dan G. Duda

Supplementary Fig. S11: Cxcr3 in CD8 T cells mediates the benefit of GC/ICB combination therapy in orthotopic murine 425-ICC model.

Funding

National Institutes of Health (NIH)

U.S. Department of Defense (DOD)

Cholangiocarcinoma Foundation

History

ARTICLE ABSTRACT

Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti–programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary tract cancers but with low response rates. Here, we studied the effects of anti–cytotoxic T lymphocyte antigen (CTLA)-4 when combined with anti–PD-1 and gemcitabine/cisplatin in orthotopic murine models of ICC. This combination therapy led to substantial survival benefits and reduction of morbidity in two aggressive ICC models that were resistant to immunotherapy alone. Gemcitabine/cisplatin treatment increased tumor-infiltrating lymphocytes and normalized the ICC vessels and, when combined with dual CTLA-4/PD-1 blockade, increased the number of activated CD8+Cxcr3+IFNγ+ T cells. CD8+ T cells were necessary for the therapeutic benefit because the efficacy was compromised when CD8+ T cells were depleted. Expression of Cxcr3 on CD8+ T cells is necessary and sufficient because CD8+ T cells from Cxcr3+/+ but not Cxcr3–/– mice rescued efficacy in T cell‒deficient mice. Finally, rational scheduling of anti–CTLA-4 “priming” with chemotherapy followed by anti–PD-1 therapy achieved equivalent efficacy with reduced overall drug exposure. These data suggest that this combination approach should be clinically tested to overcome resistance to current therapies in ICC patients.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC